Medical device developer NeuroWave Systems is targeting a series A investment of up to $5 million to fund the European commercialization of its flagship anesthesia- and sedation-monitoring device. Cleveland Heights, Ohio-based NeuroWave’s NeuroSense patient-monitoring device is aimed at reducing anesthesia complications. The company last year received the CE Mark and has already signed a European distributor for its brain-monitoring system. Now the company needs to step up sales and marketing of the system, and would use the series A round in part to fund an unspecified number of hires in those areas, CEO Tatjana Zikov said.